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Abstract. 
 
Because mutations in Rab27a have been
linked to immune defects in humans, we have examined
 
cytotoxic lymphocyte function in 
 
ashen
 
 mice, which con-
tain a splicing mutation in Rab27a. 
 
Ashen 
 
cytotoxic T
 
lymphocytes (CTLs) showed a 
 
.
 
90% reduction in lytic
activity on Fas-negative target cells compared with con-
trol C3H CTLs, and 
 
ashen
 
 natural killer cell activity was
likewise diminished. Although their granule-mediated
cytotoxicity pathway is profoundly defective, 
 
ashen
 
CTLs displayed a normal FasL–Fas cytotoxicity path-
way. The CD4/8 phenotype of 
 
ashen
 
 T cells and their
proliferative responses were similar to controls. 
 
Ashen
 
CTLs had normal levels of perforin and granzymes A
and B and normal-appearing perforin-positive granules,
which polarized upon interaction of the CTLs with anti–
CD3-coated beads. However, rapid anti–CD3-induced
granule secretion was drastically defective in both
 
CD8
 
1
 
 and CD4
 
1
 
 T cells from 
 
ashen
 
 mice. This defect in
exocytosis was not observed in the constitutive pathway,
as T cell receptor–stimulated interferon-
 
g
 
 secretion was
normal. Based on these results and our demonstration
that Rab27a colocalizes with granzyme B-positive gran-
ules and is undetectable in 
 
ashen
 
 CTLs, we conclude
that Rab27a is required for a late step in granule exocy-
tosis, compatible with current models of Rab protein
function in vesicle docking and fusion.
Key words: lymphocyte • cytotoxicity • Rab • exocy-
tosis • myosin V
 
Introduction
 
Cytotoxic T lymphocytes (CTLs)
 
1
 
 and natural killer (NK)
cells lyse target cells by exocytosing specialized secretory
granules containing perforin and granzymes into a syn-
apse-like junction that forms between the lymphocyte and
the bound target cell (Henkart et al., 1997; Stinchcombe
and Griffiths, 1999). Death of the target cell requires per-
forin-dependent membrane permeabilization, followed by
granzyme-dependent proteolysis of critical cytoplasmic
substrates (Henkart et al., 1997). In addition to this gran-
ule-mediated pathway, CTLs also possess a second cyto-
toxic pathway in which T cell receptor (TcR) engagement
induces expression of Fas ligand, which crosslinks Fas on
the target cell surface, triggering apoptosis.
Several human diseases have been identified that in-
volve defects in lymphocyte-mediated cytotoxicity via the
granule exocytosis pathway. One such disease is Griscelli’s
syndrome, a rare autosomal recessive disease character-
ized by partial albinism in conjunction with other symp-
toms (Klein et al., 1994). Although the cause of this
disease was originally identified as a mutation in the
unconventional myosin, myosin Va (Pastural et al., 1997),
recent work has shown that patients classified with this
syndrome can have either of two different mutations (Me-
nasche et al., 2000; Pastural et al., 2000). Although a small
fraction of patients have mutations in myosin Va, the ma-
jority have mutations in Rab27a, a relatively uncharacter-
ized Rab family member previously identified in melano-
cytes and cells of hematopoetic origin (Nagata et al., 1990;
Chen et al., 1997). Rab GTPases reside on the surface of
vesicles and organelles in the endocytic and secretory
pathways, where they play critical roles in the targeting
and fusion of these vesicles with their appropriate accep-
tor membrane by participating in the formation and/or
function of SNARE complexes (Schimmoller et al., 1998;
Chavrier and Goud, 1999). Importantly, although both
types of Griscelli’s patients exhibit partial albinism, only
those with mutations in Rab27a exhibit T cell hyperprolif-
eration and defects in lymphocyte cytotoxicity (Menasche
et al., 2000).
Recently, the mouse coat color mutant 
 
ashen
 
 was shown
to be caused by a mutation in Rab27a (Wilson et al., 2000).
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inosinic acid; TcR, T cell receptor; ZVAD-FMK, carbobenzoxy-valyl-ala-
nyl-aspartyl (
 
O
 
-methyl)-fluoromethyl ketone. 
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Ashen
 
 mice exhibit a reduction in coat color intensity, an
abnormal perinuclear distribution of melanosomes, the
pigment-producing organelle of melanocytes, and a pro-
found deficit in dense granules and their components
within platelets. 
 
Ashen
 
 mice contain a single point muta-
tion that prevents the proper splicing of Rab27a tran-
scripts (Wilson et al., 2000). In an effort to define in a
more precise way the role of Rab27a in lymphocyte-medi-
ated cytoxicity, we have characterized CTLs from 
 
ashen
 
mice with regard to granule biogenesis, distribution, and
release, and with regard to cytotoxic function in vitro
 
 
 
via
the granule-mediated and Fas pathways.
 
Materials and Methods
 
Antibodies and Other Reagents
 
Unless otherwise specified, anti–mouse lymphocyte surface antibodies
were purchased from BD PharMingen, as was recombinant IL-7. The
sources of other antibodies were as follows: anti–mouse CTLA-4 (R&D
Systems); antiperforin KM585 (Kamaya); anti-granzyme B (Santa Cruz
Biotechnology, Inc.); anti-Rab27a (Signal Transduction Labs); and Texas
red goat anti–rat IgG, donkey anti–goat IgG, and FITC-goat anti–mouse
IgG (Jackson ImmunoResearch). Anti-CD3x–anti-TNP heteroconjugate
was a gift from Dr. David Segal (National Cancer Institute, Bethesda,
MD). The sources of other reagents were as follows: recombinant IL-2
(Boehringer); polystyrene beads (6.5 
 
m
 
m) (Polysciences, Inc.); carboben-
zoxy-valyl-alanyl-aspartyl (
 
O
 
-methyl)-fluoromethyl ketone (ZVAD-FMK)
(Enzyme Systems); and concanamycin A (Alexis).
 
Mice, Cell Lines, and Lymphocytes
 
C3H/
 
ashen
 
 mice and their parental strain C3H/HeSnJ (C3H), as well as
C57Bl/6J (B6), were obtained from The Jackson Laboratory. B6 mice het-
erozygous for the 
 
dilute
 
 allele d
 
l20J
 
, a functional null allele for the myosin
Va heavy chain, were a gift of Neal Copeland and Nancy Jenkins (Na-
tional Cancer Institute). The murine lymphomas L1210, L1210-Fas, and
EL4 were maintained in RPMI 1640 supplemented with 10% FCS, 100 IU
penicillin, and 10 
 
m
 
g/ml streptomycin. CTLs were generated from in vitro
mixed lymphocyte cultures, which in the case of a
 
shen
 
 and control C3H
mice were established after priming with 2 
 
3 
 
10
 
7
 
 EL-4 cells i.p. 10–14 d
previously. Splenic responder cells from mutant and wild-type mice (1 ml
at 2 
 
3
 
 10
 
6
 
 cell/ml) were mixed with 1 ml of 
 
g
 
-irradiated stimulator spleen
cells at 4 
 
3
 
 10
 
6
 
 cells/ml (B6 for C3H and 
 
ashen
 
, BALB/c for B6 and 
 
di-
lute
 
). Cells were then cultured in 24-well plates in complete medium for
5 d at 37
 
8
 
C in 5% C0
 
2
 
 incubator. Viable cells were isolated by lympholyte
separation medium (Cedarlane Laboratories), and either used at this
stage, or cultured for another 48 h in the presence of 0.8 ng/ml rIL-7 and
25 U/ml rIL-2 (7-d mixed lymphocyte reaction [MLR] cells). CD8
 
1
 
 or
CD4
 
1
 
 cells were purified by positive magnetic bead selection using CD4
and CD8 microBeads and the VarioMac Cell sorting system (Miltenyi
Biotec).
 
Cytotoxicity Assays, Granule Contents,
and Degranulation
 
All target cells were labeled with Chromium-51 to detect lysis, and the
CTL targets L1210 and L1210-Fas were TNP-modified by reaction with 1
mM trinitrobenzene sulfonate in PBS, pH 7.4, for 15 min to allow redi-
rected lysis using 100 ng/ml anti-CD3x–anti-TNP heteroconjugate. Effec-
tor lymphocytes and 10
 
4
 
 targets were incubated in 96-well plates for 4 h at
37
 
8
 
C in 5% C0
 
2
 
, and the percent of supernatant Chromium-51 release was
calculated with correction for background lysis. In some experiments, 50
 
m
 
M ZVAD-FMK was added, whereas in others, CTLs were pretreated
with concanamycin A (1 
 
m
 
M) for 2 h before being added to target cells in
the continued presence of the drug. NK activity was measured on spleno-
cytes harvested 24 h after i.p. injection of 50 
 
m
 
g of polycytidylic-inosinic
acid (poly I:C) (Sigma-Aldrich). Proliferation of splenic T cells was mea-
sured by culture of splenocytes at 2 
 
3 
 
10
 
6
 
/ml in complete medium in flat-
bottom 96-well plates. For MLR, wells contained 4
 
 3 
 
10
 
6
 
 irradiated
C57Bl/6 splenocytes. For anti-CD3 induced proliferation, wells were pre-
 
coated with anti-CD3 (10 
 
m
 
g/ml) or a mixture of anti-CD3 plus anti-CD28.
After 3 d, wells were pulsed with 5 
 
m
 
Ci [
 
3
 
H]thymidine for 8 h and har-
vested with a Mach IIM harvester (TOMTEC).
The granzyme A content of purified CD8
 
1
 
 T cells was determined from
800 
 
g
 
 supernatants of cells treated with 0.1% Triton X-100 for 10 min on
ice. Its enzymatic activity was measured by addition of 100 
 
m
 
l of superna-
tant to 50 
 
m
 
l of 0.5 mM dithiobis-(2-nitrobenzoic acid) (Sigma-Aldrich) in
0.15 M NaCl, 0.01 M Hepes, pH 7.5, followed by addition of 50 
 
m
 
l of 200
 
m
 
M of Cbz-lysine-thiobenzyl ester (Sigma-Aldrich). Absorbance at 405
nm was measured with a Victor Multiscan (Wallac Instruments) plate
reader after 30 min at 21
 
8
 
C. The amounts of perforin, granzyme B, and
Rab27a in purified CD8
 
1
 
 cell lysates were estimated by Western blotting
using ECL reagents (Amersham Pharmacia Biotech). To measure degran-
ulation, purified CD8
 
1
 
 or CD4
 
1
 
 7-d MLR T cells were added to flat-bot-
tom wells coated with 10 
 
m
 
g/ml anti-CD3 or control hamster IgG, and
supernatants were harvested at indicated times. For measuring degranula-
tion by 
 
b
 
-hexosaminidase release, supernatants (100 
 
m
 
l) were added to
100 
 
m
 
l of 1 mM methylumbelliferyl-
 
N
 
-acetyl-
 
b
 
-
 
D
 
-glucosaminide substrate
(Sigma-Aldrich) diluted in 2% Triton-X 100 in 0.25 M citrate, pH 4.8. Af-
ter incubation for 1 h at 37
 
8
 
C, the fluorescence (355/460 nm) was mea-
sured with the Victor plate reader. The supernatant 
 
b
 
-hexosaminidase
was expressed as a percentage of the total enzyme in 0.1% Triton X-100
lysates. The same supernatants were also tested for 
 
g
 
-IFN secretion by
ELISA using mAb 37895.11 (Sigma-Aldrich) as a capture antibody and
goat anti–mouse 
 
g
 
-IFN (Sigma-Aldrich) as a detecting antibody, with per-
oxidase-labeled pig anti–goat IgG (Sigma-Aldrich).
 
Flow Cytometry and Immunofluorescence
 
CD4/8 phenotyping was carried out by incubating 1 
 
m
 
g of appropriate an-
tibody with 10
 
6
 
 cells in 100 
 
m
 
l followed by flow cytometry with a FAC-
Scan
 
®
 
 (BD Biosciences). For anti–CTLA-4 staining, 7-d MLR cells were
harvested and incubated with 10 
 
m
 
g/ml biotinylated anti–CLTA-4 anti-
body for 1 h. As a negative control, cells were incubated with 10 
 
m
 
g/ml
nonbiotinylated anti-CTLA-4. Cells were then incubated with 1 
 
m
 
g of
streptavidin-PE for 30 min and analyzed by flow cytometry.
For fluorescence microscopy, cells in suspension (10
 
6
 
/ml) were plated
in four-well poly-
 
L
 
-lysine chamber slides and fixed with 4% paraformalde-
hyde. Cells were then washed and blocked for 15 min in three changes of
PBS containing 10% FCS. Cells were incubated sequentially for 1 h each
in primary (1:100) and secondary antibodies (1:200) in blocking buffer
containing 0.2% saponin (with a 15 min wash in between). After antibody
staining, samples were washed and mounted using antifade mounting me-
dium (SlowFade; Molecular Probes). Samples were viewed using a ZEISS
LSM 510 confocal microscope.
Anti-CD3–coated beads were prepared by washing 6.5 
 
m
 
m polystyrene
beads (Polysciences, Inc.) with PBS and then incubating overnight at 10
 
7
 
/
ml in PBS with 10 
 
m
 
g/ml purified anti-CD3 mAb 2C11. After washing, the
beads were resuspended at 4 
 
3 
 
10
 
6
 
 beads/ml in 0.5% BSA in HBSS. Puri-
fied CD8
 
1
 
 7-d MLR CTL at 8
 
 3 
 
10
 
6
 
/ml were added at a 4:1 cell/bead ratio
in this buffer. After incubation for the indicated time at 37
 
8
 
C, they were
fixed, stained, and analyzed as above.
 
Results and Discussion
 
Defective Granule Exocytosis–based Cytolytic Activity 
in CTL and NK Cells from Ashen but Not Dilute Mice
 
CTLs from 
 
ashen
 
 mice were compared with C3H controls
for their ability to lyse Fas-negative L1210 target cells us-
ing redirected cytotoxicity. 
 
Ashen
 
 CTLs showed a pro-
found defect in target cell lysis, corresponding to 
 
.
 
90%
loss of lytic potency as seen by horizontal comparison of
the titration curves (Fig. 1 A). A similar deficiency was
observed using allospecific EL-4 target cells to measure
direct TcR–mediated cytotoxicity (data not shown). NK
activity of spleen cells from 
 
ashen
 
 mice was also de-
creased 
 
z
 
10 times compared with controls (Fig. 1 B).
These results imply that Rab27a is expressed in both T
cell and NK lymphocyte lineages and is required for cyto-
toxicity via the granule exocytosis cytotoxicity pathway. 
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To examine if the FasL–Fas cytotoxicity pathway is de-
fective in 
 
ashen
 
 CTLs, the cytotoxic activity of 
 
ashen
 
CTLs on Fas-bearing target cells was examined. Fig. 1 C
shows that 
 
ashen
 
 CTLs do kill a Fas-expressing transfec-
tant of the L1210 target cells used in Fig. 1 A, although
not nearly as well as do C3H controls. When concanamy-
cin A was used to abolish the granule exocytosis cytotox-
icity pathway (Kataoka et al., 1996), cytotoxic activity of
C3H CTL was reduced to the level of
 
 ashen
 
 CTLs, which
in turn was unaffected by this drug. These results show
that the FasL–Fas cytotoxicity pathway is normal in
 
ashen
 
 cells, whereas the granule exocytosis pathway is
defective. In the presence of ZVAD-FMK, 
 
ashen
 
 CTLs
showed no activity on L1210-Fas, confirming that this ac-
tivity occurs via the FasL–Fas lytic pathway (Sarin et al.,
1997). When both concanamycin A and ZVAD-FMK
were added to the C3H CTL, lytic activity was totally
abolished (data not shown). The lysis of L1210-Fas by
 
ashen
 
 CTLs was not seen in the absence of anti-hapten–
anti-CD3 heteroconjugate (data not shown), confirming
 
the requirement for TcR cross-linking for FasL expres-
sion in 
 
ashen
 
 CTLs. Together, these experiments show
that 
 
ashen
 
 CTLs have an intact FasL–Fas cytotoxicity
pathway even though their granule exocytosis cytotoxic-
ity pathway is abolished, and argue against a general de-
fect in TcR signaling in the 
 
ashen
 
 CTL. These results also
suggest that the FasL detectable in perforin-containing
CTL granules (Bossi and Griffiths, 1999) did not contrib-
ute significantly to the functional ligand on the effector
cell surface in these experiments. This makes it unlikely
that a defect in FasL surface expression due to compro-
mised degranulation contributes to the T cell hyperpro-
liferation in Griselli’s patients with mutations in Rab27a,
as might have been predicted from defects in FasL itself
(Wu et al., 1996). Identical results to those shown in Fig.
1, A and C, were obtained with purified CD8
 
1
 
 CTL (data
not shown).
 
Dilute
 
 and 
 
ashen
 
 mice exhibit identical degrees of coat
color dilution and identical defects in the distribution of
melanosomes within melanocytes (Wilson et al., 2000;
Figure 1. In vitro cytotoxicity of cy-
totoxic T and NK lymphocytes
from  ashen and dilute mice. (A) Ac-
tivity of secondary CTL from ashen
versus C3H control mice on Fas-
negative L1210 targets, redirected
with anti-CD3xanti-TNP. (B) NK
activity of spleen cells from poly
I:C–injected  ashen versus C3H
mice. (C) Activity of secondary
CTLs from ashen versus C3H con-
trol mice on Fas-transfected L1210
targets, redirected with anti-
CD3xanti-TNP. Solid circles are
hidden by solid squares symbols in
this graph. (D) Activity of primary
CTLs from dilute versus C57Bl/6
control mice on Fas-negative L1210
targets, redirected with anti-CD3x–
anti-TNP. (E) NK activity of spleen
cells from poly I:C–injected dilute
versus C57Bl/6 mice.  
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Wu et al., 2001). However, as shown in Fig.1, D and E,
the cytotoxicity of CTL and NK cells from 
 
dilute
 
 mice is
normal. Thus, exocytosis of cytotoxic lymphocyte gran-
ules does not appear to require myosin Va, in contrast to
the generation of a proper peripheral accumulation of
melanosomes within melanocytes, which requires both
myosin Va and Rab27a. These data confirm in mice the
results obtained in humans with mutations in either my-
osin Va or Rab27a, where only the latter exhibit defects
in lymphocyte-mediated cytotoxicity (Menasche et al.,
2000).
 
Ashen Thymocytes and Splenocytes Show Normal T 
Cell Phenotypes and Proliferative Responses
 
To determine whether the defective killing by 
 
ashen CTLs
was due to a defect in T cell maturation, we compared T
cell phenotypes of ashen and C3H spleens and thymus. Ta-
ble I shows that ashen thymic and splenic T cells have a
normal CD4/CD8 phenotype. Numbers of both thymocytes
and splenocytes were identical in C3H and ashen mice
(data not shown). MLR cultures showed similar expansion
of CD81 cells with ashen and C3H splenocyte responders
(Table I), and these CD81 cells showed similar increases in
expression of the activation markers CD25 and CD44 (data
not shown). Ashen and C3H splenic T cells also showed
similar proliferative responses to alloantigen and anti-CD3
(Table I). Together, these data indicate that the defective
killing by ashen CTLs is not due to obvious defects in T cell
maturation or to a general defect in the expansion of pre-
cursors during effector cell differentiation.
Ashen CTLs Lack Rab27a but Contain Granules of 
Normal Morphology and Mediator Content
The defect in granule-mediated cytotoxicity exhibited by
ashen CTLs implies that normal CTLs express Rab27a.
The Western blot in Fig. 2 B shows that Rab27a is indeed
present in C3H CD81 CTL but is undetectable in an
equivalent load of ashen CTL extract. This lack of de-
tectable Rab27a protein is compatible with the severe
defect in processing of Rab27a transcripts seen by re-
verse transcriptase–PCR in tissues from ashen mice
(Wilson et al., 2000).
The defect in the granule exocytosis cytotoxicity path-
way in ashen cytotoxic lymphocytes could be due to a
failure in the delivery of the critical effector proteins per-
forin and granzymes to the granules, or in the formation
Table I. Phenotype and Proliferation of Ashen versus C3H
T Cells
Parameter C3H* Ashen*
Thymocyte phenotype
% CD41 5.9 6 0.1 5.7 6 0.2
% CD81 1.7 6 0.5 1.7 6 0.5
% CD4181 89.1 6 3.1 88.9 6 2.8
Splenocyte phenotype, ex vivo spleen
% CD41 17.7 6 2.1 16.5 6 2.6
% CD81 10.2 6 3.3 9.9 6 4.2
Splenocyte phenotype, after 7 d MLR
% CD41 14.8 6 4.2 17.8 6 9.8
% CD81 84.1 6 11.6 81.7 6 11.4
Spleen T cell proliferation‡
MLR (aC57Bl/6) 6.6 6 0.6 8.3 6 1.1
a-CD3 13.3 6 1.2 14.8 6 1.0
a-CD3 1 a-CD28 23.5 6 1.8 23.1 6 1.8
*Data shown are mean 6 SD.
‡cpm 3 103, day 3.
Figure 2. Expression of gran-
ule proteins and Rab27a in pu-
rified CD81 CTLs from ashen
versus C3H control mice. (A)
Granzyme A activity of Triton
X-100 lysates of CTLs from
ashen versus C3H control
mice. Activity levels were de-
termined from the linear por-
tion of plots of activity versus
cell number. (B) Western blot
analysis of granzyme B, per-
forin, and Rab 27a from puri-
fied CD81 CTLs. (C and D)
Immunofluorescent detection
of intracellular perforin in
ashen  and C3H CTL, showing
normal appearance of ashen
CTL granules. Projected im-
ages are shown. Bar, 2.3 mm.Haddad et al. Defective Exocytosis in Rab27a-deficient Lymphocytes 839
of the granules themselves, especially since platelets
from  ashen mice exhibit a dramatic reduction in the num-
ber of dense granules (Wilson et al., 2000). To address
this possibility, we compared the levels of granule-
expressed granzymes A and B and perforin in purified
CD81 CTL from ashen and C3H mice. Granzyme A en-
zymatic activity on a per cell basis was the same in ashen
and C3H CTLs (Fig. 2 A). Granzyme B and perforin lev-
els as determined by Western blot analysis (Fig. 2 B)
were equal or greater in ashen CTLs relative to C3H
controls. Furthermore, perforin-positive granules were
present in similar numbers and appearance in ashen and
C3H CTLs (Fig. 2, C and D). Therefore, we conclude
that Rab27a is not required for the biogenesis of effector
granules in CTLs.
The defect in the granule exocytosis cytotoxicity exhib-
ited by ashen CTLs could also be due to the inability of
granules to polarize to the site of target cell contact
(Kupfer and Singer, 1989). We found that ashen CTLs can
polarize their secretory granules upon contact with anti-
CD3–coated beads (data not shown). Because this polar-
ization is difficult to quantify, we cannot exclude the possi-
bility that Rab27a contributes to the efficiency of this
process, but we can conclude that it is not absolutely re-
quired for granule polarization to occur.
TcR-induced Granule Exocytosis Is Undetectable in 
CD81 and CD41 Ashen T Cells, Whereas Interferon-g 
Secretion Is Normal
CTL granule exocytosis induced by TcR cross-linking can
be measured by release of granule enzymes into the super-
natant after incubation on anti-CD3–coated surfaces. Fig.
3 A shows that TcR-triggered granule exocytosis, mea-
sured by supernatant release of the granule marker b-hex-
osaminidase is undetectable in activated T cells from
ashen mice. Fig. 3 B shows that when these same superna-
tants were analyzed for g-interferon, which is rapidly se-
creted by the constitutive pathway after TcR cross-linking
Figure 3. Anti-CD3 induced
secretion in activated T cells
from  ashen versus C3H mice. T
cells from 7-d secondary MLR
cultures were incubated on
wells coated with anti-CD3 or
control hamster IgG. Secre-
tion was determined from en-
zyme activity in supernatants,
expressed as a percentage of
levels in Triton X-100 cell ly-
sates. (A) Time course of b-hex-
osaminidase release from
ashen versus C3H T cells. (B)
Supernatants from the experi-
ment in A were analyzed for
g-interferon. (C) Purified CD41
and CD81 T cells were tested
for b-hexosaminidase secretion
after 4 h of incubation. (D) Se-
cretion of the granule marker
granzyme A in purified CD41
and CD81 after 4 h.
Figure 4. Immunofluorescence detection of Rab 27a and granzyme B in CD81 C3H CTLs. (A) Granzyme B, red. (B) Rab 27a, green.
(C) Colocalization of granzyme B and Rab 27a (yellow). Projected images are shown. Bar, 4.6 mm.The Journal of Cell Biology, Volume 152, 2001 840
(Fortier et al., 1989), no difference was observed between
ashen and C3H CTLs. Thus, although Rab27a is required
for the TcR-triggered exocytosis of granules containing
preformed secretory products, it is not required for TcR-
induced gene expression and exocytosis of the vesicles as-
sociated with the constitutive secretory pathway. These re-
sults also strengthen the case that TcR signaling is normal
in ashen T cells.
Although lymphocyte granule exocytosis has been asso-
ciated with cytotoxicity and has been described principally
in CD81 T cells, we found that purified CD41 and CD81 T
cells from 7-d MLR cultures have roughly equivalent lev-
els of total b-hexosaminidase on a per cell basis. As shown
in Fig. 3 C, when tested for TcR-stimulated secretion, puri-
fied activated CD41 as well as CD81 T cells from C3H
mice showed a clear increase in supernatant release of
b-hexosaminidase. However, comparable cells from ashen
mice showed no secretion of this granule marker by either
subpopulation. Fig. 3 D shows similar results for the gran-
ule marker granzyme A, which was also secreted in re-
sponse to phorbol 12-myristate 13-acetate and ionomycin
in C3H but not ashen CTLs (data not shown). Together
with defective NK cytotoxicity (Fig. 1 B), our results show
that CD41 and CD81 T cells, as well as NK cells, all re-
quire Rab27a for granule exocytosis. These data further
extend the findings of defective granule exocytosis in acti-
vated T cells from Rab27a-deficient humans (Menasche et
al., 2000).
Rab27a Localizes to Granzyme-containing Granules
in CTLs
To determine whether Rab27a is present on cytotoxic lym-
phocyte secretory granules, we double stained CD81
CTLs for Rab27a and granzyme B. Fig. 4 shows that
Rab27a exhibits strong colocalization with this effector
granule marker, indicating that a large portion of cellular
Rab27a resides on the surface of these granules.
TcR-induced Surface Expression of CTLA-4 Is Normal 
in Activated Ashen T Cells
After TcR ligation, T cells express CTLA-4 on their sur-
face, which engages B7 family ligands and generates nega-
tive signals ending the interaction with antigen presenting
cells. CTLA-4 knockout mice have a lethal lymphoprolif-
erative disease (Waterhouse et al., 1995), confirming a role
for CTLA-4 in limiting T cell proliferation. CTLA-4 has
been localized to perforin-containing granules in CD81
CTLs (Linsley et al., 1996), and is expected to be ex-
pressed on the surface by a granule exocytosis process af-
ter TcR cross-linking. To assess the possibility that T cell
hyperproliferation in Griscelli’s patients bearing Rab27a
mutations is due to a decrease in surface expression of
CTLA4 secondary to defective granule exocytosis, we ex-
amined TcR-induced CTLA-4 surface expression in acti-
vated T cells from ashen and C3H mice. Fig. 5 shows that
such cells from both strains have minimal basal CTLA-4
surface expression and that TcR cross-linking induces an
equally large increase in surface CTLA-4 expression in
both ashen and control T cells. Thus, a defect in CTLA-4
surface expression due to defective granule exoctyosis is
unlikely to explain the hyperproliferation of T cells seen in
Griscelli’s syndrome patients with Rab27a mutations.
In conclusion, our results show that Rab27a functions at
a late stage in the regulated secretion of granule media-
tors, but not in the constitutive secretory pathway. Unlike
the case with platelet dense granule biogenesis, granules
form normally in ashen CTLs and contain a normal com-
plement of mediators. These granules polarize in response
to TcR cross-linking and are associated with Rab 27a in
wild-type CTLs. Our results argue that the principal site of
action of Rab27a in the immune system is in cytotoxic lym-
phocytes and that it functions at a late step in the fusion of
granules with the plasma membrane. This step could in-
volve the Rab27a-dependent formation and/or function of
the SNARE pair mediating granule–plasma membrane fu-
Figure 5. Anti-CD3 induced surface
CTLA-4 expression in ashen versus C3H
control mice. Secondary MLR-activated T
cells from ashen and C3H mice were cul-
tured on immobilized anti-CD3 for 4 h,
stained for CTLA-4 without permeabiliza-
tion, and analyzed by flow cytometry.
Heavy line, cells stained with biotinylated
anti–CTLA-4 and PE-streptavidin. Light
line, cells stained with nonbiotinylated anti–
CTLA-4 and PE-streptavidin.Haddad et al. Defective Exocytosis in Rab27a-deficient Lymphocytes 841
sion. Our results also shed light on the molecular etiology
of the fatal human hyperproliferative syndrome resulting
from mutations in Rab27a.
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